Clinical Trials Browser

Not yet recruiting × disitamab vedotin × Clear all

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT07142200 2025-08-26

DECIDING

Phase 2 Not yet recruiting

Neoplasms

NCT06957561 2025-05-04

DIVON

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06385873 2024-05-13

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06015113 2023-08-29

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Phase NA Not yet recruiting

Breast Neoplasms

NCT05912205 2023-06-22

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT05488353 2022-08-04

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Phase 4 Not yet recruiting

Urinary Bladder Neoplasms